February 04, 2021
Patients with cancer, including hematologic, breast, and lung cancer, who present with STEMI fare just as well with primary PCI as those without cancer, according to the results of a new study.
While primary PCI is underutilized in this high-risk group, with just half of lung cancer patients, for example, taken to the cath lab for revascularization, researchers found there was no significant difference in the risk of in-hospital major adverse cardiovascular and cerebrovascular events or all-cause mortality based on whether STEMI patients had cancer.
“Overall, these findings should provide some reassurance or evidence for operators who might be more cautious and potentially worried about causing harm in this high-risk group,” lead investigator Mohamed O. Mohamed, MBBCh (Keele University/Royal Stoke University Hospital, Stoke-on-Trent, England), told TCTMD.